Get started
Author

Elizabeth Summers

Observed names: Elizabeth J Summers, Elizabeth J. Summers, Summers, Elizabeth J.
OpenAlex ID: A5032028131
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
2023 · Priscilla K. Brastianos, Albert E. Kim, et al. · Nature Medicine · 66
PDF
The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis
2023 · Magali A de Sauvage, Consuelo Torrini, et al. · Neuro-Oncology · 10
PDF
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance
2023 · Albert E Kim, Kevin W Lou, et al. · Neuro-Oncology · 8
PDF
Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A
2025 · Christian Migliarese, Yinon Sadeh, et al. · Acta Neuropathologica Communications · 6
PDF
Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab/relatlimab.
2025 · Erika Yamazawa, Justine Vanessa Cohen, et al. · Journal of Clinical Oncology · 2
Nimg-76. a Deep Learning Algorithm for Fully Automated Volumetric Measurement of Meningioma Burden
2023 · Mason Cleveland, Albert Kim, et al. · Neuro-Oncology · 2
PDF
INNV-13. Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab and relatlimab
2025 · Erika Yamazawa, Justine Cohen, et al. · Neuro-Oncology · 1
PDF
Ctim-02. Phase 2 Trial of Pembrolizumab for Patients With Brain Metastases of Diverse Histologies
2023 · Priscilla Brastianos, Albert Kim, et al. · Neuro-Oncology · 1
PDF
Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis
2026 · Consuelo Torrini, Naema Nayyar, et al. · Neuro-Oncology Advances
Combination treatment with RAF/MEK inhibitor avutometinib and FAK inhibitor defactinib in preclinical models of meningioma
2026 · Nazanin Ijad, Katie L Waller, et al. · Neuro-Oncology Advances
EXTH-57. Evaluation of a novel CNS penetrant YAP/TEAD-targeted therapy for lung cancer brain metastases
2025 · Consuelo Torrini, Naema Nayyar, et al. · Neuro-Oncology
DDDR-71. Dual inhibition of RAF/MEK and FAK signaling improves survival in intracranial meningioma models
2025 · Nazanin Ijad, Katie L Waller, et al. · Neuro-Oncology
PDF
Exth-41. Combination Treatment With Raf/mek and Fak Inhibition Enhances Tumor Growth Inhibition in Meningioma
2024 · Nazanin Ijad, Katie L Waller, et al. · Neuro-Oncology
PDF
Csig-12. Yap1-tead Signaling Contributes to Lung Cancer Colonization of the Brain
2024 · Consuelo Torrini, Naema Nayyar, et al. · Neuro-Oncology
PDF
Dddr-04. Preclinical Investigation of a Novel Brain Penetrant Combination Therapy Targeting Raf and Mek for Melanoma Brain Metastasis
2024 · Erika Yamazawa, Naema Nayyar, et al. · Neuro-Oncology
PDF
Dddr-32. Evaluating the Therapeutic Effects of Small Molecule Inhibitors of Cdk4/6 and Fak in Preclinical Meningioma Models
2023 · Nazanin Ijad, Katie Waller, et al. · Neuro-Oncology
PDF
Exth-45. Development of Combination Therapies of Krasg12c Inhibitor Adagrasib in Preclinical Models of Brain Metastasis
2023 · Consuelo Torrini, Christian Migliarese, et al. · Neuro-Oncology
PDF
Exth-42. Preclinical Investigation of a Novel Brain Penetrant Mek Inhibitor to Target Brain Metastasis
2023 · Erika Yamazawa, Naema Nayyar, et al. · Neuro-Oncology
PDF
Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy
2023 · Albert E. Kim, Kevin W. Lou, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Works count: 21
Citation count: 96
H-index: 4
I10-index: 2
Year
Topic
Type